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Abstract
Background: Cluster Headache (CH) is a severe primary headache, with a poorly understood pathophysiology.
Complex genetic factors are likely to play a role in CH etiology; however, no confirmed gene associations have
been identified. The aim of this study is to identify genetic variants influencing risk to CH and to explore the
potential pathogenic mechanisms.
Methods: We have performed a genome-wide association study (GWAS) in a clinically well-defined cohort of 99
Italian patients with CH and in a control sample of 360 age-matched sigarette smoking healthy individuals, using
the Infinium PsychArray (Illumina), which combines common highly-informative genome-wide tag SNPs and exonic
SNPs. Genotype data were used to carry out a genome-wide single marker case-control association analysis using
common SNPs, and a gene-based association analysis focussing on rare protein altering variants in 745 candidate
genes with a putative role in CH.
Results: Although no single variant showed statistically significant association at the genome-wide threshold, we
identified an interesting suggestive association (P = 9.1 × 10−6) with a common variant of the PACAP receptor gene
(ADCYAP1R1). Furthermore, gene-based analysis provided significant evidence of association (P = 2.5 × 10−5) for a
rare potentially damaging missense variant in the MME gene, encoding for the membrane metallo-endopeptidase
neprilysin.
Conclusions: Our study represents the first genome-wide association study of common SNPs and rare exonic
variants influencing risk for CH. The most interesting results implicate ADCYAP1R1 and MME gene variants in CH
susceptibility and point to a role for genes involved in pain processing. These findings provide new insights into
the pathogenesis of CH that need further investigation and replication in larger CH samples.
Keywords: Cluster headache, Association studies in genetics, Genome-Wide Association Study, Pituitary adenylate
cyclase-activating polypeptide receptor (ADCYAP1R1), Membrane metalloendopeptidase (MME), Neprylisin, Missense
mutation
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Background
Cluster Headache (CH) is a primary headache with a
mean prevalence of 0.1% among general population and
a clear male predominance [1]. It is characterized by se-
vere unilateral retro-orbital or fronto-temporal pain at-
tacks, occurring even eight times a day and associated
with homolateral autonomic signs [2]. Pain attacks show
a circadian and seasonal rhythmicity and smoking is the
most frequent life-time habit in CH patients with a
prevalence over 80%.
The biology of CH is poorly understood. Current hy-
potheses are focused on vasomotor changes, inflamma-
tion, immune changes, autonomic system imbalance and
hypothalamic dysfunction [3]. Twin and family studies
have indicated the importance of genetic factors in CH
[1]. Genetic predisposition seems to be complex, with the
environment and genetic factors interacting together [1].
Association studies focussing on candidate genes have
suggested a possible role for HCRTR2 [4–6], not con-
firmed in a recent meta-analysis [7]. No associations or
conflicting results were found for variants in CACNA1A
[8], NOS [9], MTHFR [10], PER3 [11], SERPINA [12],
and ADH4 [13, 14] genes.
Given the largely unknown pathophysiology of CH, we
have undertaken a whole-genome approach to identify
the underlying genetic determinants in a clinically well-
defined cohort of 99 Italian patients with CH. A cohort
of 360 healthy Italian individuals, composed of age-
matched cigarette smokers, was used as a control sam-
ple. We have used the Infinium PsychArray (Illumina)
[15], which combines both common highly-informative
genome-wide tag single-nucleotide polymorphisms
(SNPs) and exonic SNPs, with an enrichment in genetic
variants associated with common psychiatric conditions.
This approach thus offers greater potential for the iden-
tification of rare or common variants with phenotypic
effects in CH.
Methods
Study samples
One hundred patients with CH were enrolled at the Div-
ision of Toxicology and Clinical Pharmacology, Head-
ache Centre, University of Modena and Reggio Emilia
(Italy). CH diagnosis was made following the ICHD-III
beta criteria [2]. CH patients clinical assessment in-
cluded sex, age, headache history (age of onset, duration
of the active phase, highest number of clusters per day
and per month, triggering factors, associated autonomic
symptoms, correlation with cigarette smoking in the ac-
tive phase), drug treatment history and smoking status
(number of cigarettes per day, CPD, and Fagerström test
for nicotine dependence, FTND [16]). The control sam-
ple consisted of 360 age-matched Italian smokers, not
suffering from CH or migraine, recruited at the same
centre as part of a study on the genetics of nicotine de-
pendence (RF-2009‐1549619). All participants were of
self-reported Italian ancestry and provided a written in-
formed consent to participate. This study was approved
by the local Ethical Committee and took place in obser-
vation of the declaration of Helsinki (protocol number
2224/2013).
Genotyping and quality control procedures
DNA for genotyping was extracted from blood or saliva.
Genotyping was performed on Illumina Infinium® Psy-
chArray microarrays (Illumina, San Diego, California,
USA) in two batches, the first using Illumina
PsychArray-24 v1.0, the second using PsychArray-24 v1-
1 array [15]. We limited our analysis to 566178 variants
present on both versions of the array. Content for the
Infinium PsychArray includes 265,000 proven tag SNPs
found on the Infinium Core-24 BeadChip, 245,000
markers from the Infinium Exome-24 BeadChip, and
50,000 additional markers associated with common psy-
chiatric disorders.
The clustering algorithm implemented in GenomeStu-
dio was used to cluster the data. Array clustering and
quality control (QC) was performed according to recom-
mended guidelines [17] (see Additional file 1 for details).
The overall data quality was high: only one control DNA
sample failed QC thresholds (one additional CH sample
was subsequently removed because of non-European
ethnicity); 10 replicate pairs of samples undergoing
genotyping were assessed for consistency and reproduci-
bility of the assay and agreement of genotyping calls was
99.99% over all genotypes across these pairs. Principal
component analysis (PCA) was performed using PLINK
1.9 [18] on SNPs with minor allele frequency (MAF) >
0.01, pruned for linkage disequilibrium (200 kb window
size, r2 > 0.5). PCA plots were generated using the
Genesis tool [19]. One outlying sample was identified
and excluded from subsequent association analysis
(Additional file 1: Figure S1). Relatedness among sub-
jects was checked using PLINK –genome option. 458
samples (99 cases, 359 controls) and 556485 variants
pass filters and QC, of these 211927 are monomorphic
and were excluded from association analysis.
Sanger sequencing was used to screen the MME cod-
ing region in all CH affected individuals. Primers se-
quences are available from the authors upon request.
Association analysis
Single marker SNP association analysis was performed
using the PLINK v 1.9 software [18]. Basic case-control
analysis was performed on 290505 SNPs that passed
QC and MAF > 0.01 using Fisher’s exact test. Results
from the association analysis were clumped according to
P-value using PLINK. Each clump is represented by an
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index variant (that with the lowest P-value in the clump),
and contains all SNPs with P-value < 0.01 in linkage dis-
equilibrium with it (R2 > 0.5, within 250 kb of the index
SNP). Logistic regression was performed using PLINK –
logistic command. To correct for multiple testing we
applied the Bonferroni correction (P < 1.7 × 10−7, corre-
sponding to 0.05/number of analyzed SNPs). Quantile-
quantile (Q-Q) plot for test statistics was performed using
the R package; the regional association plot was created
using LocusZoom [20].
Gene-based association analysis was conducted using
the Sequence Kernel Association Test (SKAT) [21],
which aggregates individual score test statistics of a set
of SNPs and efficiently computes gene-level p-values.
Post QC, non-monomorphic SNPs were mapped to
RefSeq genes (downloaded from the UCSC Table
Browser, GRCh37/hg19). SKAT analysis was restricted to
a comprehensive collection of candidate genes with a
plausible role in CH pathogenesis. The selection of can-
didate genes was based on Gene Ontology (GO) bio-
logical process annotations (http://geneontology.org/
page/download-annotations). We selected a group of
1038 genes annotated with sixty-six GO terms impli-
cated in pain perception and response, blood pressure
regulation and vasodilation/vasoconstriction, circadian
rhythms, alcohol metabolism, neuropeptide signalling, ion
channels, nicotinic acetylcholine receptors, tumour necro-
sis factor (TNF) signalling. The complete list of candidate
genes and GO annotations is listed in Additional file 1:
Table S1. Gene-based analysis was conducted on all
protein altering variants (non-synonymous and spli-
cing variants) with MAF <0.05 within these candidate
genes, for a total of 2568 variants in 745 candidate
genes (Additional file 1: Table S2). These included 2497
missense, 11 frameshift, 40 stopgain, 3 stoploss, and 17
splicing variants. We used a Bonferroni correction based
on the number of the evaluated genes to assess the signifi-
cance of the gene-based test results (p < 6.7 × 10−5). Func-
tional annotation of variants was performed using
Polyphen-2 [22] and the Combined Annotation–
Dependent Depletion method (CADD) [23]. CADD is a
tool for scoring the deleteriousness of variants in the hu-
man genome by incorporating a variety of algorithms in
an integrated score (C score).
Results
After stringent quality control filtering and exclusion of
211927 monomorphic SNPs, 344558 high quality SNPs
were retained for genetic association analysis for CH dis-
ease susceptibility. The population sample included 99
individuals with CH and 359 controls. Demographic and
clinical characteristics are summarized in Table 1. We
conducted genome-wide association tests for single
SNPs, as well as gene-based tests focussing on a subset
of rare protein altering variants (PAVs), which a priori,
are more likely to impact on disease status.
Genome wide association analysis
Single marker case-control association analysis was per-
formed on high quality SNPs with minor allele frequency
(MAF) > 0.01 (290505 SNPs) in the study population,
using the Fisher exact test (Additional file 1: Table S3).
Calculation of the genomic inflation factor indicated
no overall inflation of the genome-wide statistical results
(λ =1), and the Q-Q plot displayed no global departure
from the expected null distribution of P-values (Additional
file 1: Figure S2). Both of these results indicate negligible
inflation of the genome-wide association signals caused by
Table 1 Sample characteristics
Cluster headache patients Controls
N 99 359
Gender (N,%)
Male 83, 83.84% 204, 56.82%
Female 16, 16.16% 155, 43.18%
Age, ys (mean ± sd, range) 47.39 ± 13.12, 23–81 48.96 ± 11.91, 18–70
CH attacks
Age at onset, ys (mean ± sd, range) 30.04 ± 12.65, 6–80
Chronic (N, %) 14, 14.14%
N attacks/year (mean ± sd, range) 1.29 ± 0.77, 0.17–4
N attacks/day (mean ± sd, range) 2.85 ± 1.68, 1–9
Smoking
Ever smoking (N,%) 88, 88.89% 359, 100%
N cigarette/day (mean ± sd) 19.17 ± 10.83 21.77 ± 9.13
Fagerström test (mean ± sd); N 4.60 ± 2.54 (N = 72) 5.95 ± 2.21
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population stratification. Overall association results are
shown in the Manhattan plot (Fig. 1). Although no single
variant showed statistically significant association at the
genome-wide threshold (P < 1.7 × 10−7), we identified
some suggestive associations (P < 10−5). Results of the top
loci are shown in Table 2. A SNP cluster tagged by
rs1006417 on chromosome 14 was the most significant hit
(P = 1.4 × 10−6), located in a gene poor region with no
known genes (Additional file 1: Figure S3). The second
suggestive hit was for an intronic SNP in the ADCYAP re-
ceptor type I gene (ADCYAP1R1), encoding for pituitary
adenylate cyclase-activating peptide (PACAP) receptor
(Additional file 1: Figure S3). Because CH patients are
more frequently males, the male:female ratio differed in
the cases and controls, we thus performed a logistic re-
gression analysis with adjustment for sex as a covariate.
This analysis confirmed the chromosome 14 locus as the
most significant result while the significance of the
ADCYAP1R1 SNP was somewhat decreased (Additional
file 1: Table S4), suggesting a possible sex effect at this
locus. Adding adjustment for age and CPD to the logistic
regression model provided similar results.
Notably, our dataset did not provide support to previ-
ously reported putative association signals for CH in
the HCRTR2 and ADH4 genes. None of the genotyped
SNPs mapping to these genes, including the previously
implicated SNPs rs2653349 (G1246A) in HCRTR2 and
rs1126671 in ADH4, reached a nominally significant
P-value (Additional file 1: Table S3).
We also investigated a possible overlap with genetic sus-
ceptibility to migraine. A recent meta-analysis identified
45 independent confirmed SNPs that map to 38 distinct
loci [24], of which 29 were directly genotyped or captured
by a tag SNP in our study. Only rs9349379 in PHACTR1
achieved a nominally significant P value (P = 0.034)
(Additional file 1: Table S5).
Furthermore, given the relationship between CH and
tobacco smoke, we hypothesized that genetic risk factors
involved in smoking-related traits might also have a pos-
sible role in CH susceptibility. We inspected the
CHRNA5-CHRNA3-CHRNB4 cluster, the CHRNA6-
CHRNB3 cluster and CHRNA4, which are genes showing
confirmed association to nicotine dependence and smok-
ing behaviours [25–27]. However, no allelic imbalance
was detected between CH cases and control smokers
at any of the tested polymorphic variants (including
the functional non-synonymous SNP rs16969968)
(Additional file 1: Table S3). Given the availability of
smoking measures in our sample, we also tested if an
effect of these variants on smoking quantity (CPD) or
nicotine dependence (FTND) was detectable in our
sample. Linear regression analysis, with adjustment
for sex, age, and CH case status, did not reveal any
signal (data not shown).
Fig. 1 Manhattan plot of genome-wide association P-values. The y axis represents the -log10 Fisher’s test P-values; the horizontal line indicates the
threshold for suggestive significance (P < 10−5)
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Gene based analysis
To increase power to identify disease causing variants,
we restricted our analysis to rare (MAF < 0.05) PAVs
mapping to a comprehensive collection of candidate
genes associated to cellular processes with a plausible
role in CH, including pain perception and response,
vasodilation and vasoconstriction, circadian rhythms,
alcohol metabolism, neuropeptide signalling, ion chan-
nels, nicotinic acetylcholine receptors, TNF signalling
(Additional file 1: Table S1). A total of 2568 rare PAVs
belonging to 745 candidate genes were included in
gene-based analysis using SKAT [21], which produces a
gene-level P value that indicates the degree of enrich-
ment of rare variant associations for SNPs within a
gene (Additional file 1: Table S1). The most significant
results (nominal P-value < 0.001) are shown in Table 3. The
membrane metalloendopeptidase gene (MME), was the
most significant gene with nominal P value of 2.5 × 10−5,
which survived Bonferroni correction for multiple testing
(P = 0.019). All the individual SNPs contributing to the
gene-level tests (Table 3) had good genotyping cluster
properties and genotyping rate > 99.9%. Interestingly, the
most significant SNP (rs147564881) is a missense variant
in MME (NM_000902.3:c.674G >C, p.G225A), which was
found in 3.5% (7/99) CH patients and in none of 359
Italian controls. This variant is very rare in the general
population (MAF = 0.1% in all 1000 Genome Project
phase 3 individuals, 0.2% in 60,706 individuals of the
Exome Aggregation Consortium ExAC), and has a pos-
sible damaging effect based on bioinformatic tools; the
CADD PHRED-scaled C score is > 20, thus ranking in
the top 1% of predicted deleteriousness of all possible
single nucleotide variants [23]. The MME variants were
confirmed by Sanger sequencing of the entire MME
coding region in all CH patients; no additional rare
variant was detected except for a synonymous SNP
(rs200455903). Clinical details of the seven CH patients
heterozygous for the c.674G > C (p.G225A) variant are
shown in Additional file 1: Table S6; these subjects did
not show significant differences in clinical aspects dis-
tinguishing them from the rest of the CH patient sam-
ple. Other nominal suggestive results (p < 0.01) were
identified, including NPY1R (Neuropeptide Y receptor
type 1), BDKRB1 (B1 bradykinin receptor), SLC5A3
(Sodium/myo-inositol cotransporter), CCL26 (C-C
motif chemokine 26) and GRM1 (Metabotropic glutam-
ate receptor 1) (Table 3).
Discussion
At present, the molecular genetic background of CH
remains a largely unexplored field. Molecular genetic in-
vestigations of CH have been in part hampered by the
complex nature of the disorder and have been confined
to single candidate gene studies. GWAS offer a
hypothesis-free alternative to candidate gene studies and
have recently brought novel insights into the biological
and genetic underpinnings of many complex traits, in-
cluding migraine [24]. However, most GWAS have fo-
cussed on common variants in the general population
(>5%) with a modest effect on risk, hence requiring very
large sample sizes. The diffusion of exome sequencing
technology provided evidence for the role of rare coding
variants in the aetiology of several complex diseases, and
a cost effective alternative to exome sequencing is pro-
vided by the recent development of “exome” genotyping
arrays, which were created to genotype rare coding vari-
ants identified by exome sequencing of thousands of
individuals [28]. Thus, in order to comprehensively in-
vestigate genetic factors influencing risk to CH, we have
used the Illumina PsychArray [15] that allows testing
genome-wide common variants as well as low frequency
exonic variants: the combination of these two features
results in a gain in power, given the unknown genetic
architecture of CH. Genotype data were exploited to
carry out single marker genome-wide association tests
using common SNPs, as well as gene-based association
analysis focussing on rare exonic variants in candidate
genes with a putative role in CH.
Table 2 Association analysis results of SNPs with suggestive genome-wide significance
Index SNP Position Other SNPs in clump Gene A 1 A 2 A1-F case/controls A1-F 1000G_all
(1000G_EUR)a
P-value OR (95% CI)
rs1006417 14:41803291 rs1782180, rs1779522,
rs1778408, rs11157219,
rs715334, rs12433558
G A 0.11/0.26 0.19 (0.19) 1.40 × 10−6 0.34 (0.21–0.55)
rs12668955 7:31116168 ADCYAP1R1 G A 0.34/0.52 0.55 (0.50) 9.10 × 10−6 0.48 (0.34–0.66)
rs1495452 3:65834076 MAGI1 A G 0.55/0.38 0.39 (0.45) 1.43 × 10−5 2.03 (1.48–2.79)
rs2182605 1:117463537 PTGFRN G A 0.32/0.50 0.51 (0.48) 1.80 × 10−5 0.49 (0.35–0.68)
rs16895584 8:122518935 A G 0.24/0.04 0.070 (0.054) 1.85 × 10−5 3.50 (2.03–6.02)
rs6469999 8:122415207 rs13255877, rs7833779 A G 0.31/0.17 0.46 (0.16) 2.16 × 10−5 2.23 (1.56–3.19)
rs1509957 10:64610718 rs224308, rs10822065 G A 0.60/0.43 0.43 (0.49) 2.66 × 10−5 1.99 (1.44–2.74)
Abbreviations: A1 minor allele in study sample, A2 major allele, A1-F A1 frequency, OR odds ratio for minor allele, CI confidence interval
aAllele 1 frequency in 1000 Genomes phase 3, all populations (1000G_all) and european population (1000G_EUR)
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The most interesting result stemming from genome-
wide analysis was a suggestive association of CH with a
common variant of the PACAP receptor gene
(ADCYAP1R1); furthermore, gene-based analysis pro-
vided evidence for a rare variant of the MME gene. Both
gene products are known to have a pivotal function in
pain mechanisms, thus making these associations par-
ticularly stimulating.
PACAP is a peptide involved in pain-processing in ani-
mal models [29], and recently proposed to contribute to
Table 3 Results of SKAT gene-based tests in CH
SNP SKAT
P-value
Single SNPs
P-valuea
RA RAF case/
control
RAF 1000G_all
(1000G_EUR)b
RAF in ExAC_all
(ExAC_NFE)c
Function PolyPhen-2
(Prediction)d
CADD
scoree
GeneMME
(NM_000902.3)
2.55 × 10−5
rs61762319 0.42 G 0.030/0.021 0.0072(0.023) 0.0164(0.0226) Missense c.22A >
G (p.M8V)
0.524(P) 15.63
rs147564881 2.03 × 10−5 C 0.035/0 0.001(0.002) 0.0022(0.0033) Missense c.674G >
C (p.G225A)
1 (D) 21
rs61758194 1 A 0/0.0014 0.0002(0) 0.0021(0.0035) Missense c.1033G >
A (p.V345I)
0.001(B) 11.65
Gene NPY1R
(NM_000909.5)
1.18 × 10−3
rs5578 3.80 × 10−3 C 0.040/0.0084 0.003(0.007) 0.0047(0.0067) Missense c.1121A >
C (p.K374T)
0.421(B) 12.96
rs78156188 1 A 0/0.0028 0.0004(0.002) 0.0006(0.001) Missense c.332C >
T (p.A111V)
0.023(B) 3.073
Gene BDKRB1
(NM_000710.3)
3.30 × 10−3
rs143823168 1 C 0/0.0028 0.0018(0.003) 0.0024(0.0036) Missense c.571C >
G (p.L191V)
0.999(D) 9.214
rs45528332 9.23 × 10−3 A 0.030/0.0056 0.0036(0.004) 0.0062(0.0052) Missense c.721G >
A (p.G241R)
0.926(P) 9.661
Gene SLC5A3
(NM_006933.6)
4.94 × 10−3
rs35707420 0.014 A 0.025/0.0042 0.0026(0.006) 0.0062(0.0087) Missense c.1108G >
A(p.V370M)
1(D) 18.46
rs199948762 0.39 G 0.0051/0.0014 . 0.000099 (0.0001) Missense c.1671C >
G(p.N557K)
0.001(B) 8.533
Gene CCL26
(NM_006072.4)
7.02 × 10−3
rs41463245 0.022 A 0.020/0.0028 0.0036(0.016) 0.0086(0.0131) Nonsense c.132G >
A (p.W44X)
. 23.1
Gene GRM1
(NM_000838.3)
9.45 × 10−3
rs41305288 0.017 A 0.035/0.0098 0.01(0.017) 0.0172(0.0185) Missense c.2185C >
A (p.P729T)
1(D) 19.24
rs362936 1 A 0.0051/0.0097 0.004(0.017) 0.0212(0.031) Missense c.2651G >
A (p.G884E)
0.998(D) 13.22
rs138759146 1 C 0/0.0014 . 0.0001(0.0002) Missense c.2725A >
C (p.M909L)
0.017(B) 1.328
rs2941 0.14 A 0.0051/0.022 0.0092(0.025) 0.0132(0.0182) Missense c.2785G >
A (p.V929I)
0.111(B) 18.3
rs79336287 0.071 A 0.015/0.0023 0.005(0.004) 0.0017(0.0013) Missense c.3206C >
T (p.P1069L)
0(B) 11.39
Abbreviations: RA rare allele, RAF rare allele frequency
aSingle SNP Fisher's exact test P-value
bRare allele frequency in 1000 Genomes all populations (1000G_all) and european populations (1000G_EUR)
cRare allele frequency in Exome Aggregation Consortium (ExAC) Non-Finnish European (NFE) populations
d HumDiv score; B benign, P possibly damaging, D probably damaging
eCADD v1.3, PHRED-like (-10*log10(rank/total)) scaled C-score
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migraine pathogenesis [30]. Notably, PACAP administra-
tion in healthy subjects induces migraine-like headache
[31]. PACAP, through PACAP receptor, induces activation
of neurons in the superior salivatory nucleus, sphenopala-
tine and Gasser ganglion [32], that is thought to be a cru-
cial event in CH pathophysiology, and higher PACAP
plasma levels were detected during ictal phase than during
inter-bout periods in CH patients [33].
MME encodes for a zinc-dependent plasma membrane
endopeptidase, also known as neprilysin or neutral
endopeptidase (NEP), that hydrolyses several extracellu-
lar peptides. They include peptides, such as substance P,
neuropeptide Y, bradykinin, enkephalins, and atrial and
brain natriuretic peptides [34], involved in the central
regulation of pain, vasomotion, stress and sleep-wake
rhythms as well as in the modulation of trigeminal noci-
ceptive signals, whose alterations are thought to be im-
plied in CH and to lead to the principal clinical features
of this disease [3, 35, 36]. Interestingly, constitutive NEP
knockout mice showed enhanced response to noxious
thermal and chemical stimuli as well as thermal hyper-
algesia and allodynia, and mechanical allodynia after
chronic constriction injury of sciatic nerve [37]. The
MME c.674G > C (p.G225A) missense variant was absent
in our unaffected controls, but it is represented at low
frequency in public control datasets (MAF = 0.02%); al-
though the prevalence of primary headache in public
datasets is unknown, this could reflect incomplete pene-
trance and the interaction with other genetic or environ-
mental factors. Furthermore, rare loss-of-function and
missense MME variants were recently associated to late
onset dominant axonal polyneuropathies (Charcot-Marie-
Tooth Neuropathy Type 2, CMT2; spinocerebellar ataxia
with neuropathy, SCA43) [38, 39] and to a rare autosomal
recessive variant of CMT2 [40]; none of the neuropathy
patients described in these studies was reported to have
migraine or CH symptoms, however individuals with
MME mutations were reported to experience painful sen-
sations [38]. Given the variety of NEP target peptides and
their wide expression pattern, it is plausible that MME
deleterious variants may contribute to the aetiology of dif-
ferent neurological conditions, and further studies are
needed to identify the mechanisms underlying the pheno-
typic differences. We can speculate that while severe, very
rare deleterious mutations lead to axonal polyneuropa-
thies, the more prevalent c.674G > C (p.G225A) missense
variant might have a milder damaging effect, increasing
CH susceptibility by interaction with other environmental
or genetic factors.
Conclusions
In conclusion, our work provides the first evidence that
genetic variants in genes involved in pain processing
could confer susceptibility to CH. A major limitation in
our study is the relatively small sample size, hence fur-
ther investigation in larger cohorts is warranted in order
to confirm our initial association results.
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single marker P-values of all tested SNPs. Table S4. logistic regression
analysis. P-values for additive effect of SNPs controlling for sex as a covariate
(P sex), and for sex, age and cigarettes per day (P sex, age, CPD). Table S5.
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susceptibility SNPs emerged in meta-analysis. Figure S1. Principal
component analysis (PCA) plot. Figure S2. Quantile-quantile (Q-Q)
plot of Fisher’s exact test P-values for association with cluster headache
(CH). Figure S3. Local association plots for chromosome 14 locus (A) and
the chromosome 7 locus (B) [17, 18, 24, 41]. (ZIP 6890 kb)
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association study; MAF: Minor allele frequency; MME: Membrane
metalloendopeptidase gene; NEP: Neutral endopeptidase;
NPY1R: Neuropeptide Y receptor type 1; PACAP: Pituitary adenylate cyclase-
activating peptide; PAV: Protein altering variant; PCA: Principal component
analysis; QC: Quality control; Q-Q: Quantile-quantile; SCA43: Spinocerebellar
ataxia with neuropathy; SKAT: Sequence Kernel Association Test;
SLC5A3: Sodium/myo-inositol cotransporter; SNP: Single-nucleotide
polymorphism; TNF: Tumour necrosis factor
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